Notice of Special Interest: Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)
(NOT-OD-21-020)
National Institutes of Health
Food and Drug Administration
John E. Fogarty International Center
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
National Library of Medicine
Office of Behavioral and Social Sciences Research
Office of Research on Women's Health
Funding Opportunities
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
(PA-21-071)
National Institutes of Health
John E. Fogarty International Center
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Library of Medicine
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s):
Due dates vary by awarding IC
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)
(PAR-21-022)
National Institute on Drug Abuse
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
Application Receipt Date(s):
July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)
(PAR-21-023)
National Institute on Drug Abuse
National Institute on Alcohol Abuse and Alcoholism
Application Receipt Date(s):
J?uly 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed)
(PAR-21-025)
National Institute of General Medical Sciences
Application Receipt Date(s):
February 26, 2021; January 28, 2022; January 30, 2023, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)
(PAR-21-065)
National Cancer Institute
Application Receipt Date(s):
Standard dates apply
The first standard due date for this FOA is January 25, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)
(PAR-21-066)
National Cancer Institute
Application Receipt Date(s):
Standard dates apply
The first standard due date for this FOA is January 25, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
(PAR-21-067)
National Cancer Institute
Application Receipt Date(s):
Standard dates apply
The first standard due date for this FOA is January 25, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Biological Testing Facility (X01 Clinical Trial Not Allowed)
(PAR-21-078) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s):
January 15, 2021, July 15, 2021, ?January 14, 2022, July 15, 2022
Diabetes Research Centers (P30 Clinical Trial Optional)
(RFA-DK-20-025)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s):
May 20, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)
(RFA-DK-20-033)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s):
March 31, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Contraceptive Development Research Centers Program (P50 Clinical Trial Optional)
(RFA-HD-22-003) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s):
November 29, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
(RFA-MH-21-105)
National Institute of Mental Health
Office of Research on Women's Health
Application Receipt Date(s):
February 9, 2021
All applications are due by 5:00 PM local time of applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
(RFA-MH-21-106)
National Institute of Mental Health
Office of Research on Women's Health
Application Receipt Date(s):
February 9, 2021
All applications are due by 5:00 PM local time of applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R01 Clinical Trial Optional)
(RFA-MH-21-151)
National Institute of Mental Health
National Institute on Drug Abuse
National Institute on Minority Health and Health Disparities
Office of Behavioral and Social Sciences Research
Office of Research on Women's Health
Application Receipt Date(s):
Only accepting applications for the AIDS Application Due Date listed below.?